BethLongeneckerDO

PubMed

• 4 citations
  A rat model to study the role of STn antigen in colon cancer.
  Shunichiro Ogata, Immanuel Ho, Joseph Maklansky, Anli Chen, J. Lawrence Werther, Mark A. Reddish, B. Michael Longenecker, Elin R. Sigurdson, Seichiro Iishi, Jie-Yu Zha...> ;Glycoconjugate Journal. 2001 Nov 1
• Glycosylations versus conformational preferences of cancer associated mucin core.
  Schuman, J., Qiu, D., Koganty, R. R., Longenecker, B. M., Campbell, A. P.> ;Glycoconj J. 2000 Dec
• Association of MUC-1 and SPGL-1 with low-density microdomain in T-lymphocytes: a preliminary note.
  Handa, K., Jacobs, F., Longenecker, B. M., Hakomori, S. I.> ;Biochem Biophys Res Commun. 2001 Jul 20
• Anti-MUC-1 immunoliposomal doxorubicin in the treatment of murine models of metastatic breast cancer.
  Moase, E. H., Qi, W., Ishida, T., Gabos, Z., Longenecker, B. M., Zimmermann, G. L., Ding, L., Krantz, M., Allen, T. M.> ;Biochim Biophys Acta. 2001 Feb 9
• A low-level expression of human MUC1 mucin enhances lethality of murine tumor cells.
  Zimmermann, G. L., Krantz, M. J., Kane, K. P., Longenecker, B. M.> ;Cancer Immunol Immunother. 2000 Aug
• Clinical outcome of breast and ovarian cancer patients treated with high-dose chemotherapy, autologous stem cell rescue and THERATOPE STn-KLH cancer vaccine.
  Holmberg, L. A., Oparin, D. V., Gooley, T., Lilleby, K., Bensinger, W., Reddish, M. A., MacLean, G. D., Longenecker, B. M., Sandmaier, B. M.> ;Bone Marrow Transplant. 2000 Jun
• Anti-T antibodies and peanut-agglutinin-binding glycoproteins in sera of patients with gastric cancer.
  Hwang, I. R., Nahm, D. H., Cho, S. N., Longenecker, B. M., Rao Koganty, R., Park, I. S.> ;J Cancer Res Clin Oncol. 1999 Oct
• Vaccines prepared with sialyl-Tn and sialyl-Tn trimers using the 4-(4-maleimidomethyl)cyclohexane-1-carboxyl hydrazide linker group result in optimal antibody titers a...
  Ragupathi, G., Howard, L., Cappello, S., Koganty, R. R., Qiu, D., Longenecker, B. M., Reddish, M. A., Lloyd, K. O., Livingston, P. O.> ;Cancer Immunol Immunother. 1999 Apr
• Evidence of a cellular immune response against sialyl-Tn in breast and ovarian cancer patients after high-dose chemotherapy, stem cell rescue, and immunization with Th...
  Sandmaier, B. M., Oparin, D. V., Holmberg, L. A., Reddish, M. A., MacLean, G. D., Longenecker, B. M.> ;J Immunother. 1999 Jan
• Rapid induction of primary human CD4+ and CD8+ T cell responses against cancer-associated MUC1 peptide epitopes.
  Agrawal, B., Krantz, M. J., Reddish, M. A., Longenecker, B. M.> ;Int Immunol. 1998 Dec
• MUC1 synthetic peptide inhibition of intercellular adhesion molecule-1 and MUC1 binding requires six tandem repeats.
  Kam, J. L., Regimbald, L. H., Hilgers, J. H., Hoffman, P., Krantz, M. J., Longenecker, B. M., Hugh, J. C.> ;Cancer Res. 1998 Dec 1
• The anti-MUC1 monoclonal antibody BCP8 can be used to isolate and identify putative major histocompatibility complex class I associated amino acid sequences.
  Agrawal, B., Reddish, M. A., Christian, B., VanHeele, A., Tang, L., Koganty, R. R., Longenecker, B. M.> ;Cancer Res. 1998 Nov 15
• The biological role of mucins in cellular interactions and immune regulation: prospects for cancer immunotherapy.
  Agrawal, B., Gendler, S. J., Longenecker, B. M.> ;Mol Med Today. 1998 Sep
• Expression of MUC1 mucin on activated human T cells: implications for a role of MUC1 in normal immune regulation.
  Agrawal, B., Krantz, M. J., Parker, J., Longenecker, B. M.> ;Cancer Res. 1998 Sep 15
• Liposomal formulations of synthetic MUC1 peptides: effects of encapsulation versus surface display of peptides on immune responses.
  Guan, H. H., Budzynski, W., Koganty, R. R., Krantz, M. J., Reddish, M. A., Rogers, J. A., Longenecker, B. M., Samuel, J.> ;Bioconjug Chem. 1998 Jul 01
• Anti-MUC1 class I restricted CTLs in metastatic breast cancer patients immunized with a synthetic MUC1 peptide.
  Reddish, M., MacLean, G. D., Koganty, R. R., Kan-Mitchell, J., Jones, V., Mitchell, M. S., Longenecker, B. M.> ;Int J Cancer. 1998 Jun 10
• Different modes of sialyl-Tn expression during malignant transformation of human colonic mucosa.
  Ogata, S., Koganty, R., Reddish, M., Longenecker, B. M., Chen, A., Perez, C., Itzkowitz, S. H.> ;Glycoconj J. 1998 Jan
• Immunogenicity and antitumor activity of a liposomal MUC1 peptide-based vaccine.
  Samuel, J., Budzynski, W. A., Reddish, M. A., Ding, L., Zimmermann, G. L., Krantz, M. J., Koganty, R. R., Longenecker, B. M.> ;Int J Cancer. 1998 Jan 19
• Cancer-associated MUC1 mucin inhibits human T-cell proliferation, which is reversible by IL-2.
  Agrawal, B., Krantz, M. J., Reddish, M. A., Longenecker, B. M.> ;Nat Med. 1998 Jan
• Analysis of the role of type 1 core O-glycans in the binding of anti-MUC1 antibodies by cytofluorometry and synthetic peptide/glycopeptide binding inhibition studies.
  Reddish, M. A., Suresh, M. R., Koganty, R. R., Fortier, S., Baronic, L., Berg, A., Longenecker, B. M.> ;Tumour Biol. 1998
• Specificities of anti-sialyl-Tn and anti-Tn monoclonal antibodies generated using novel clustered synthetic glycopeptide epitopes.
  Reddish, M. A., Jackson, L., Koganty, R. R., Qiu, D., Hong, W., Longenecker, B. M.> ;Glycoconj J. 1997 Aug
• Prognostic significance of preimmunotherapy serum CA27.29 (MUC-1) mucin level after active specific immunotherapy of metastatic adenocarcinoma patients.
  MacLean, G. D., Reddish, M. A., Longenecker, B. M.> ;J Immunother. 1997 Jan
• Specificity analysis of murine monoclonal antibodies reactive with Tn, sialylated Tn, T, and monosialylated (2-->6) T antigens.
  O'Boyle, K. P., Markowitz, A. L., Khorshidi, M., Lalezari, P., Longenecker, B. M., Lloyd, K. O., Welt, S., Wright, K. E.> ;Hybridoma. 1996 Dec
• A randomised phase II study of sialyl-Tn and DETOX-B adjuvant with or without cyclophosphamide pretreatment for the active specific immunotherapy of breast cancer.
  Miles, D. W., Towlson, K. E., Graham, R., Reddish, M., Longenecker, B. M., Taylor-Papadimitriou, J., Rubens, R. D.> ;Br J Cancer. 1996 Oct
• Enhancing the effect of THERATOPE STn-KLH cancer vaccine in patients with metastatic breast cancer by pretreatment with low-dose intravenous cyclophosphamide.
  MacLean, G. D., Miles, D. W., Rubens, R. D., Reddish, M. A., Longenecker, B. M.> ;J Immunother Emphasis Tumor Immunol. 1996 Jul
• Join now to see all